Dr. Jim Russell
Professor, Department of Medicine, UBC
Dr. Russell is Professor of Medicine at University of British Columbia (UBC) and a Principal Investigator in the Centre for Heart Lung Innovation (HLI) at St. Paul’s Hospital where he focuses on septic shock research. Dr. Russell is ranked # 1 in the world in septic shock (http://expertscape.com/ex/septic+shock), vasopressin (http://expertscape.com/ex/vasopressin) and norepinephrine (http://expertscape.com/ex/norepinephrine) according to the independent expert site (expertscape).
In 1982, he founded the Critical Care Medicine (CCM) division at UBC and St. Paul’s, which he has grown to be ranked the # 1 septic shock group in the world. Dr. Russell has three major current themes of research (1) randomized controlled trials in patients with septic shock and now COVID-19, (2) biomarkers of septic shock and COVID-19, and (3) the interaction of diabetes and sepsis/septic shock.
The COVID-19 pandemic led to three CIHR-funded studies of the safety and effectiveness of angiotensin receptor blockers (ARBs) and angiotensin converting enzyme (ACE) inhibitors in COVID-19 in (1) a pan-Canadian observational cohort and (2) a pan-Canadian randomized controlled trial of losartan (an ARB) vs. usual care in adults hospitalized with COVID-19. Dr. Russel is also funded to evaluate the interactions of biological sex with outcomes of COVID-19.
Dr. Russell’s has 280 peer-reviewed journal publications, 45 book chapters (including the chapter on septic shock in Cecil Medicine), 200 research abstracts and 277 invited talks. Dr. Russell has applied this research beyond the lab to improve patient health outcomes by co-founding two spin-off biotech companies: Sirius Genomics Inc. (focused on discovery and development of predictive biomarkers for drugs in sepsis) and Cyon Therapeutics (development of a PCSK9 inhibitor in sepsis). These commercialization efforts generated employment and training opportunities, and raised the profile of Canada’s biotechnology on the world stage.
Dr. Russell’s publications highlight (1) direct high impact on care of critically ill septic patients around the world by publication in high impact journals and (2) most important, illustrate the fundamental strategy of his research career, the successful coupling of expertise in clinical trials and discovery of novel biomarkers that explain mechanisms of therapies in sepsis.
Dr. Russell is Professor of Medicine at University of British Columbia (UBC) and a Principal Investigator in the Centre for Heart Lung Innovation (HLI) at St. Paul’s Hospital where he focuses on septic shock research. Dr. Russell is ranked # 1 in the world in septic shock (http://expertscape.com/ex/septic+shock), vasopressin (http://expertscape.com/ex/vasopressin) and norepinephrine (http://expertscape.com/ex/norepinephrine) according to the independent expert site (expertscape).
In 1982, he founded the Critical Care Medicine (CCM) division at UBC and St. Paul’s, which he has grown to be ranked the # 1 septic shock group in the world. Dr. Russell has three major current themes of research (1) randomized controlled trials in patients with septic shock and now COVID-19, (2) biomarkers of septic shock and COVID-19, and (3) the interaction of diabetes and sepsis/septic shock.
The COVID-19 pandemic led to three CIHR-funded studies of the safety and effectiveness of angiotensin receptor blockers (ARBs) and angiotensin converting enzyme (ACE) inhibitors in COVID-19 in (1) a pan-Canadian observational cohort and (2) a pan-Canadian randomized controlled trial of losartan (an ARB) vs. usual care in adults hospitalized with COVID-19. Dr. Russel is also funded to evaluate the interactions of biological sex with outcomes of COVID-19.
Dr. Russell’s has 280 peer-reviewed journal publications, 45 book chapters (including the chapter on septic shock in Cecil Medicine), 200 research abstracts and 277 invited talks. Dr. Russell has applied this research beyond the lab to improve patient health outcomes by co-founding two spin-off biotech companies: Sirius Genomics Inc. (focused on discovery and development of predictive biomarkers for drugs in sepsis) and Cyon Therapeutics (development of a PCSK9 inhibitor in sepsis). These commercialization efforts generated employment and training opportunities, and raised the profile of Canada’s biotechnology on the world stage.
Dr. Russell’s publications highlight (1) direct high impact on care of critically ill septic patients around the world by publication in high impact journals and (2) most important, illustrate the fundamental strategy of his research career, the successful coupling of expertise in clinical trials and discovery of novel biomarkers that explain mechanisms of therapies in sepsis.
